Jane Street’s Kite Pharma, Inc. KITE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-84,746
| Closed | -$15.2M | – | 5573 |
|
|
2017
Q3 | $15.2M | Buy |
84,746
+12,400
| +17% | +$1.73M | 0.05% | 359 |
|
|
2017
Q2 | $7.5M | Buy |
72,346
+60,010
| +486% | +$4.9M | 0.03% | 580 |
|
|
2017
Q1 | $968K | Buy |
+12,336
| New | +$763K | ﹤0.01% | 2103 |
|
|
2016
Q4 | – | Sell |
-13,465
| Closed | -$661K | – | 4932 |
|
|
2016
Q3 | $752K | Buy |
+13,465
| New | +$750K | ﹤0.01% | 2303 |
|
|
2016
Q2 | – | Sell |
-15,981
| Closed | -$785K | – | 4912 |
|
|
2016
Q1 | $734K | Sell |
15,981
-5,369
| -25% | -$260K | ﹤0.01% | 2171 |
|
|
2015
Q4 | $1.32M | Buy |
21,350
+11,843
| +125% | +$834K | 0.01% | 1456 |
|
|
2015
Q3 | $529K | Buy |
9,507
+3,957
| +71% | +$249K | ﹤0.01% | 2254 |
|
|
2015
Q2 | $338K | Sell |
5,550
-8,153
| -59% | -$465K | ﹤0.01% | 2682 |
|
|
2015
Q1 | $790K | Buy |
+13,703
| New | +$918K | 0.01% | 1589 |
|
|
2014
Q4 | – | Sell |
-35,346
| Closed | -$1.01M | – | 3335 |
|
|
2014
Q3 | $1.01M | Buy |
+35,346
| New | +$874K | 0.01% | 933 |
|
Jane Street's KITE Position: Q4 2017 in Review
Jane Street sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 84,746 shares — an estimated $15.2M sold.
Jane Street first reported a position in KITE in Q3 2014 and held it in 10 quarters. The position peaked at $15.2M in Q3 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.
- Jane Street reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
- Jane Street sold 84,746 Kite Pharma, Inc. shares in Q4 2017, an estimated $15.2M.
- Jane Street first reported a position in Kite Pharma, Inc. in Q3 2014 and held it in 10 quarters.
- Jane Street's Kite Pharma, Inc. position peaked at $15.2M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.
Based on Jane Street's 13F filing for Q4 2017, filed 15 Feb 2018.